Ellen K Kick

List of Publications by Year
in descending order

17	735	687363 13	888059 17
papers	citations	h-index	g-index

17	17	17	909
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Discovery of Heteroaryl Urea Isosteres for Formyl Peptide Receptor 2 Agonists. ACS Medicinal Chemistry Letters, 2022, 13, 943-948.	2.8	1
2	Small molecule and macrocyclic pyrazole derived inhibitors of myeloperoxidase (MPO). Bioorganic and Medicinal Chemistry Letters, 2021, 42, 128010.	2.2	9
3	Selective FPR2 Agonism Promotes a Proresolution Macrophage Phenotype and Improves Cardiac Structure-Function Post Myocardial Infarction. JACC Basic To Translational Science, 2021, 6, 676-689.	4.1	26
4	Discovery and structure activity relationships of 7-benzyl triazolopyridines as stable, selective, and reversible inhibitors of myeloperoxidase. Bioorganic and Medicinal Chemistry, 2020, 28, 115723.	3.0	14
5	Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure. Journal of Medicinal Chemistry, 2020, 63, 9003-9019.	6.4	45
6	Preservation of Post-Infarction Cardiac Structure and Function via Long-Term Oral Formyl Peptide Receptor AgonistÂTreatment. JACC Basic To Translational Science, 2019, 4, 905-920.	4.1	32
7	Potent Triazolopyridine Myeloperoxidase Inhibitors. ACS Medicinal Chemistry Letters, 2018, 9, 1175-1180.	2.8	16
8	Triazolopyrimidines identified as reversible myeloperoxidase inhibitors. MedChemComm, 2017, 8, 2093-2099.	3.4	19
9	Beneficial and Adverse Effects of an LXR Agonist on Human Lipid and Lipoprotein Metabolism and Circulating Neutrophils. Cell Metabolism, 2016, 24, 223-233.	16.2	109
10	Discovery of Highly Potent Liver X Receptor Î² Agonists. ACS Medicinal Chemistry Letters, 2016, 7, 1207-1212.	2.8	21
11	Pharmacological Characterization of a Novel Liver X Receptor Agonist with Partial LXRÎ±Activity and a Favorable Window in Nonhuman Primates. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 305-314.	2.5	30
12	Liver X Receptor (LXR) partial agonists: Biaryl pyrazoles and imidazoles displaying a preference for LXRÎ². Bioorganic and Medicinal Chemistry Letters, 2015, 25, 372-377.	2.2	35
13	Enzymatic resolution of methyl (1RS)-N-tBoc-6-hydroxy-3,4-dihydro-1H-isoquinoline-1-carboxylate by Seaprose S. Tetrahedron: Asymmetry, 2007, 18, 2147-2154.	1.8	5
14	Identification of novel functional inhibitors of 17Î²-hydroxysteroid dehydrogenase type III (17Î²-HSD3). Prostate, 2005, 65, 159-170.	2.3	20
15	General Solid-Phase Synthesis Approach To Prepare Mechanism-Based Aspartyl Protease Inhibitor Libraries. Identification of Potent Cathepsin D Inhibitors. Journal of the American Chemical Society, 1998, 120, 9735-9747.	13.7	63
16	Structure-based design and combinatorial chemistry yield low nanomolar inhibitors of cathepsin D. Chemistry and Biology, 1997, 4, 297-307.	6.0	146
17	Expedient Method for the Solid-Phase Synthesis of Aspartic Acid Protease Inhibitors Directed toward the Generation of Libraries. Journal of Medicinal Chemistry, 1995, 38, 1427-1430.	6.4	144